Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs

Arthritis and Rheumatism

Volumn 58, Issue 4, 2008, Pages 929-938

  Song, I H ^a   Poddubnyy, D A ^a   Rudwaleit, M ^a   Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYLBUTAZONE; PIROXICAM; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB;

ACUTE KIDNEY FAILURE; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; ANALGESIA; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; ENTERITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; HEART INFARCTION; HUMAN; INFLAMMATION; LIVER TOXICITY; LONG TERM CARE; LOW BACK PAIN; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MORNING STIFFNESS; OPTIMAL DRUG DOSE; OSTEOARTHRITIS; OSTEOBLAST; PHYSIOTHERAPY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SACROILIAC JOINT; SIDE EFFECT; SKIN TOXICITY; SMALL INTESTINE DISEASE; SMOKING; SPONDYLOARTHROPATHY; STROKE; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; HUMANS; SPONDYLITIS, ANKYLOSING;

EID: 42449156632     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23275     Document Type: Review

References (51)

1. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
2. Van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52:1205-15.
3. Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999;38:235-44.
4. Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 2006;33: 1805-12.
5. Amor B, Dougados M, Listrat V, Menkes CJ, Roux H, Benhamou C, et al. Are classification criteria for spondylarthropathy useful as diagnostic criteria? Rev Rhum Engl Ed 1995;62:10-5.
6. Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, et al. Comparison of 2 different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised double-blind controlled study. Ann Rheum Dis 2007. E-pub ahead of print.
7. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
8. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000-8.
9. Boersma JW. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol 1976;5:60-4.
10. Wanders A, van der Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
11. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002;109:1405-15.
12. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
13. Rudwaleit M, Niewerth M, Listing J, Marker-Hermann E, Zeidler H, Zink A, et al. Disease activity over one year in early ankylosing spondylitis in a prospective observational cohort (GESPIC) [abstract]. Ann Rheum Dis 2005;64 Suppl 111:65.
14. Gossec L, Dougados M, Phillips C, Bayode A, Hammoudeh M, de Vlam K, et al. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1,507 rheumatologists. Ann Rheum Dis 2007. E-pub ahead of print.
15. European Medicines Agency (EMEA). EMEA press release. URL: http://www.emea.europa.eu/pdfs/human/press/pr/24732305en. pdf.
16. Food and Drug Administration (US). Proposed NSAID package insert labeling template. URL: http://www.fda.gov/cder/drug/ infopage/COX2/NSAIDRxtemplate.pdf.
17. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352: 1071-80.
18. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-35.
19. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
20. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006; 1:e33.
21. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425-30.
22. Pfizer. Protocol: a multicenter, double-blind, parallel group study comparing the incidence of clinically significant upper gastrointestinal events between celecoxib 400 mg BID and ibuprofen 800 mg TID (N49-98-02-035) or diclofenac 75 mg BID (N49-98-02-102). URL: http://www.clinicalstudyresults.org/ documents/company-study_ 1841_0.pdf.
23. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
24. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al, the MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81.
25. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al, the TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.
26. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332:1302-8.
27. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
28. Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study. Gut 1991;32:730-4.
29. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96: 1019-27.
30. Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002;55:157-63.
31. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29:804-12.
32. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, the MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;369:465-73.
33. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al, the TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
34. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
35. Lanas A, Baron JA, Sandler RS, Horgan K, Bolognese J, Oxenius B, et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 2007;132:490-7.
36. Cryer B. Nonsteroidal anti-inflammatory drug gastrointestinal toxicity. Curr Opin Gastroenterol 2001;17:503-12.
37. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101:701-10.
38. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs: a meta-analysis. Ann Intern Med 1991;115: 787-96.
39. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133-41.
40. Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:751-7.
41. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006;101:311-7.
42. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001;110 Suppl 3A:33-42S.
43. Hudson M, Rahme E, Richard H, Pilote L. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective cyclooxygenase 2 inhibitors: a class effect? Arthritis Rheum 2007;57:516-23.
44. Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol 2006;164:881-9.
45. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
46. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.
47. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-6.
48. Bjorkman D. Nonsteroidal anti-inflammatory drug-associaied toxicity of the liver, lower gastrointestinal tract, and esophagus. Am J Med 1998;105:17-21S.
49. Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005;3:489-98.
50. Novartis. Novartis withdraws Prexige (lumiracoxib) in Australia in response to decision from Therapeutic Goods Administration (TGA). URL: http://www.novartis.com.au/Prexige%20press% 20release%2011%20August.pdf.
51. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Update on sensitivity to nonsteroidal antiinflammatory drugs. Curr Drug Targets Immune Endocr Metabol Disord 2001;1:233-40.